Litigation Details for AbbVie Inc. v. Alvotech hf. (N.D. Ill. 2021)
✉ Email this page to a colleague
AbbVie Inc. v. Alvotech hf. (N.D. Ill. 2021)
| Docket | ⤷ Try a Trial | Date Filed | 2021-05-28 |
| Court | District Court, N.D. Illinois | Date Terminated | 2022-03-09 |
| Cause | 35:271 Patent Infringement | Assigned To | John Zihun Lee |
| Jury Demand | Defendant | Referred To | M. David Weisman |
| Patents | 8,231,876; 8,420,081; 8,663,945; 8,715,664; 8,808,700; 8,883,156; 8,889,136; 8,895,009; 8,906,372; 8,906,373; 8,906,646; 8,911,964; 8,916,153; 8,926,975; 8,961,973; 8,961,974; 8,986,693; 8,999,337; 9,061,005; 9,062,106; 9,067,992; 9,085,618; 9,085,619; 9,085,620; 9,090,688; 9,090,689; 9,090,867; 9,096,666; 9,102,723; 9,150,645; 9,181,337; 9,181,572; 9,187,559; 9,234,032; 9,266,949; 9,273,132; 9,284,370; 9,284,371; 9,290,568; 9,315,574; 9,328,165; 9,334,319; 9,346,879; 9,359,434; 9,499,614; 9,499,616; 9,505,834; 9,512,216; 9,522,953; 9,550,826; 9,624,295; 9,669,093; 9,683,033; 9,708,400; 9,957,318 | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in AbbVie Inc. v. Alvotech hf.
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for AbbVie Inc. v. Alvotech hf. (N.D. Ill. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-12-21 | 130 | amended complaint | U.S. Patent No. 8,231,876 72. U.S. Patent No. 8,231,876 (the “’876 patent”), titled …will constitute infringement of U.S. Patent Nos. 6,805,686, 8,231,876, 8,420,081, 8,663,945, 8,708,968, … INFRINGEMENT OF U.S. PATENT NO. 8,231,876 224. AbbVie incorporates by …DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 8,231,876 237. AbbVie incorporates by … Protector Shroud 2. 8,231,876 Wan Purified Antibody | External link to document |
| 2022-02-21 | 247 | status report | deadlines for the Ten Patents are as follows: 1 U.S. Patent Nos. 6,805,686, 8,926,975, 8,961,973, 8,999,337…with respect to ten patents that will be subject to a first trial1 (“Ten Patents”). Dkt. 63 (2258); Dkt…the ’559 and ’216 patents based on the allegations previously pled for the ’973 patent. [AbbVie…Defenses of Inequitable Conduct, Unclean Hands, and Patent Misuse in 2258 (Dkt. 69 (2258)). On January…Defenses of Inequitable Conduct, Unclean Hands, and Patent Misuse in 2899 (Dkt. 214 (2899)). The Court has | External link to document |
| 2021-11-15 | 79 | stipulation | Requests for Production related to U.S. Patent Nos. 6,805,686; 8,999,337; 9,067,992; 9,187,559; 9,512,216;…9,512,216; 11,083,792; and 11,167,030 (the patent issuing from U.S. Patent Application No. 17/137,201) (collectively…collectively, the “Remaining Patents”) by treating the term “Patents- in-Suit” as used in those Requests…served on August 25, 2021, to reflect all ten patents that will be tried in the August 2022 trial; and…Requests as including the Remaining Patents. AbbVie shall substantially complete this production on or before | External link to document |
| 2021-11-19 | 80 | other | proceeding involving the ’619 patent’s parent, U.S. Patent No. 8,420,081, lends further support to “water…indefinite, with terms in the ’792 patent being the most egregious. That patent, which AbbVie asserts covers…’s so-called “bufferless” patents, one of which, in violation of the Patent Dance confidentiality provisions… ARGUMENT The ’792 Patent The ’792 patent relates to methods for purifying … The ’619 and ’030 Patents The ’619 and ’030 patents share a common specification2 | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
